Galmed Pharmaceuticals (GLMD) Stock Statistics & Valuation Metrics

Galmed Pharmaceuticals has a market cap or net worth of $3.41M. The enterprise value is -$1.85M.

Galmed Pharmaceuticals has 2,258,034 shares outstanding. The number of shares has decreased by -2.65% in one year.

Galmed Pharmaceuticals’s return on equity (ROE) is -0.46 and return on invested capital (ROIC) is -38.45%.

The current PE Ratio of Galmed Pharmaceuticals is -0.40. Galmed Pharmaceuticals’s PEG ratio is <0.01.

In the last 12 months, Galmed Pharmaceuticals had revenue of 0.00 and earned -7.52M in profits. Earnings per share was -8.08.

In the last 12 months, operating cash flow was -5.88M and capital expenditures 0.00, giving a free cash flow of -5.88M billion.

Galmed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Galmed Pharmaceuticals upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Galmed Pharmaceuticals as a current ratio of 7.42, with Debt / Equity ratio of 0.00%

In the past 12 months, Galmed Pharmaceuticals has paid 0.00 in taxes.

Galmed Pharmaceuticals EV to EBITDA ratio is 0.23, with an EV/FCF ratio of 0.29.

Galmed Pharmaceuticals has $15.33M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$15.33M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Galmed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold